4D Molecular Therapeutics (NASDAQ:FDMT) specializes in harnessing advanced genetic engineering technologies to design targeted and proprietary AAV vectors for gene therapy. Dedicated to unlocking new treatments for various genetic disorders, the company's innovative platform aims to advance the development of gene therapy products with higher precision and effectiveness. Central to its operations are the ongoing projects that focus on addressing conditions in ophthalmology, cardiology, pulmonology, and rare diseases. 4D Molecular Therapeutics' primary objective is to create transformative gene therapeutic solutions that can lead to significant improvements in treatment outcomes for patients worldwide, reflecting its commitment to both scientific innovation and patient care.